The Red Cross’s inclusive assessment will determine blood donation eligibility; Wegovy reduces the risk of cardiovascular events; the first postpartum depression pill sparks pricing questions.
Red Cross Implements More Inclusive Blood Donation Policy
The American Red Cross is implementing a more inclusive risk-based assessment to determine blood donation eligibility, eliminating the previous ban that prevented most gay men from donating blood, according to CNN. This shift comes after decades of stigmatizing guidance from the FDA. The new policy focuses on behavior rather than sexual orientation—deferring potential donors if they have had a new sexual partner, more than one partner, or anal sex in the previous 3 months—allowing more individuals to contribute to the blood supply. Those currently taking pre- and postexposure prophylaxis also remain deferred, with the FDA highlighting the potential for false-negative results on an HIV test. Although this change is seen as a significant step toward inclusivity, some critics argue that the policy still excludes certain groups, including
Obesity Drug Wegovy Shows Cardiovascular Benefit in Major Study
Wegovy from Novo Nordisk has demonstrated an additional medical benefit beyond weight loss in a significant late-stage study, according to Reuters. The weekly injection, aimed at overweight or obese individuals with a history of heart disease, showed a 20% reduction in the risk of major cardiovascular events—including heart attack, stroke, or death from heart disease—compared with placebo. This outcome exceeded the anticipated 15% to 17% reduction. The trial involved 17,500 patients and is expected to influence insurers and health authorities to consider covering the drug’s cost for a broader patient population. Novo Nordisk plans to seek regulatory approvals for expanding Wegovy's label indication in the United States and Europe based on the study results.
Questions Linger on Pricing of Postpartum Depression Pill
The recent FDA approval of the first pill to treat postpartum depression, zuranolone (Zurzuvae), has raised concerns about its pricing, which could subsequently have an impact on its accessibility and prescription rates, according to Axios. The drug’s manufacturer, Sage Therapeutics, has yet to decide on the pricing, and this decision might be influenced by the drug's failure to gain approval for treating major depressive disorder. Analysts have revised down sales projections for zuranolone, and experts have noted that the drug’s boxed warnings and potential limitations could affect its uptake.
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More